19240-24-5

Basic information

• Product Name: L-Phenylalanine, glycyl-, methyl ester, monohydrochloride
• CAS NO: 19240-24-5
• Molecular Formula: C12H16N2O3.ClH
• Molecular Weight: 272.732
• Mol File: 19240-24-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: L-Phenylalanine, glycyl-, methyl ester, monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: L-Phenylalanine, glycyl-, methyl ester, monohydrochloride(19240-24-5)
• EPA Substance Registry System: L-Phenylalanine, glycyl-, methyl ester, monohydrochloride(19240-24-5)

Safety Data

• Hazardous Substances Data: 19240-24-5(Hazardous Substances Data)

Upstream product

• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 4833-87-8 2?(1,3?dioxoisoindolin?2?yl)acetyl methyl phenylalaninate 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 1170-76-9 Z-Gly-(L)-Phe 
• 63-91-2 L-phenylalanine 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 106624-70-8 methyl (2S)-2-[[2-(t-butoxycarbonylamino)acetyl]amino]-3-phenylpropanoate 
• 6206-42-4 N-benzyloxycarbonylglycyl-L-phenylalanine methyl ester 

Downstream Products

• 63631-32-3 (S)-methyl 12-benzyl-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oate 
• 501082-99-1 C₅₇H₆₈Cl₂N₆O₁₀ 
• 521060-85-5 C₅₅H₆₆Cl₂N₆O₉ 
• 501082-88-8 C₅₈H₇₁Cl₂N₅O₁₀ 
• 501083-17-6 estrone-3-O-CH₂CO-Tyr(2,6-dichlorobenzyl)-Gly-Gly-Phe-Leu-NH₂ 
• 501083-16-5 estrone-3-O-CH₂CO-Tyr(2,6-dichlorobenzyl)-Gly-Gly-Phe-Leu-OMe 
• 501082-91-3 2-[2-(2-{2-[2-tert-butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-acetylamino}-acetylamino)-3-phenyl-propionylamino]-4-methyl-pentanoic acid 3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl ester 
• 501083-34-7 estrone-3-O-CH₂CO-Tyr-Gly-Gly-Phe-Leu-OMe 
• 501083-33-6 estrone-3-O-CH₂CO-Tyr-Gly-Gly-Phe-Leu-OH 
• 143050-69-5 Boc-Tyr(CLz)-Gly-Gly-Phe-Leu-OH 
• 501082-80-0 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-Leu-NH₂ 
• 501082-79-7 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-Leu-OMe 
• 501082-72-0 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-OH 
• 501082-71-9 Boc-Tyr(2,6-Cl₂Bzl)-Gly-Gly-Phe-OMe 

Relevant articles and documents

Rhodium(III)-Catalyzed C-H Alkenylation: Access to Maleimide-Decorated Tryptophan and Tryptophan-Containing Peptides

Maleimide is widely applied in many fields, especially in antibody-drug conjugations and peptide drugs. Herein, we develop a strategy for the C-H alkenylation of tryptophan and tryptophan-containing peptides, providing a synthetic route of decorating male

Novel thiazolidinedione-5-acetic-acid-peptide hybrid derivatives as potent antidiabetic and cardioprotective agents

Thiazolidinediones (TZDs) are one of the important clinically established antidiabetic agents. Amino-acid and peptides have an advantage of better target selectivity and specificity. As hybrids, they also improved absorption and showed better bioavailability, which in turn makes them safer. Hence, here an effort has been made to synthesize hybrids of thiazolidinedione with amino-acids and peptides and evaluate their antidiabetic and cardioprotective effect in streptozotocin-nicotinamide (STZ-NA) induced Type 2 diabetes mellitus (T2DM) rat models. A series of 14 thiazolidinedione-5-acetic acid hybrids with of different amino-acids and peptide combinations were synthesized, characterized and further screened for antidiabetic and cardioprotective activity. Among all, six compounds T1 (SSDMA1), T4 (SSDMA4), T5 (SSDMA5), T7 (SDMA13), T9 (SSDMA15) and T13 (SSDMA49) showed better antioxidant activity and comparable % glucose uptake by yeast cells. Hence, the in vivo antidiabetic screening was done for these six compounds. Among all six T1, T7, T13 showed significant blood glucose level decrease compared to standard pioglitazone HCl. Also T1, T7 and T13 showed better antioxidant activity with lower IC50 value than standard ascorbic acid, and hence in vivo cardioprotective studies were done for these. The ECG studies showed that T1 (SSDMA1) and T7 (SSDMA13) were better effective than SDMA49 (T13) in restoring the normal functioning of the heart, thus may help in preventing the development of diabetic cardiomyopathy (DCM) and controlling T2DM.

Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.

The linkers of estrogen-GHRPs were prepared by the combination of estradiol, estrone, TyrGlyGlyPheLeuOH, and TyrGlyGlyPheLeuOH. Their anti-osteoporosis effect was evaluated by analyzing the data, for instance the weight of the body, femur, femur ash, the content of calcium and phosphor in the femur, the content of calcium and ALP activity in the serum, obtained from the corresponding bioassay in vivo. The results indicated that the anti-osteoporosis potency for estradiol, estrone, TyrGlyGlyPheLeuOH and TyrGlyGlyPheLeuNH(2) may be totally enhanced each other via the corresponding linkers.